| pubmed-article:16267021 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C1515657 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C2323499 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C1328819 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:16267021 | lifeskim:mentions | umls-concept:C1701901 | lld:lifeskim |
| pubmed-article:16267021 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:16267021 | pubmed:dateCreated | 2005-11-3 | lld:pubmed |
| pubmed-article:16267021 | pubmed:abstractText | Conditionally active forms of the Raf proteins (Raf-1, B-Raf, and A-Raf) were created by ligating NH2-terminal truncated activated forms (Delta) to the estrogen receptor (ER) hormone-binding domain resulting in estradiol-regulated constructs (DeltaRaf:ER). These different Raf:ER oncoproteins were introduced into the murine FDC-P1 hematopoietic cell line, and cells that grew in response to the three DeltaRaf:ER oncoproteins were isolated. The ability of FDC-P1, DeltaRaf-1:ER, DeltaA-Raf:ER, and DeltaB-Raf:ER cells to form tumors in severe combined immunodeficient mice was compared. Mice injected with DeltaRaf:ER cells were implanted with beta-estradiol pellets to induce the DeltaRaf:ER oncoprotein. Cytokine-dependent parental cell lines did not form tumors. Implantation of beta-estradiol pellets into mice injected with DeltaRaf:ER cells significantly accelerated tumor onset and tumor size. The recovered DeltaRaf:ER cells displayed induction of extracellular signal-regulated kinase (ERK) in response to beta-estradiol stimulation, indicating that they had retained conditional activation of ERK even when passed through a severe combined immunodeficient mouse. The DeltaRaf:ER cells were very sensitive to induction of apoptosis by the mitogen-activated protein/ERK kinase (MEK) 1 inhibitor CI1040 whereas parental cells were much less affected, demonstrating that the MEK1 may be useful in eliminating Ras/Raf/MEK-transformed cells. Furthermore, the effects of in vivo administration of the MEK1 inhibitor were evaluated and this inhibitor was observed to suppress the tumorigenicity of the injected cells. This DeltaRaf:ER system can serve as a preclinical model to evaluate the effects of signal transduction inhibitors which target the Raf and MEK proteins. | lld:pubmed |
| pubmed-article:16267021 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16267021 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16267021 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16267021 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:16267021 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:KonoplevaMari... | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:MunsellMarkM | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:AndreeffMicha... | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:ShiYuexiY | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:McCubreyJames... | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:SteelmanLinda... | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:MariniFrankF | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:SheltonJohn... | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:McQueenTeresa... | lld:pubmed |
| pubmed-article:16267021 | pubmed:author | pubmed-author:ContractorRoo... | lld:pubmed |
| pubmed-article:16267021 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16267021 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16267021 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:16267021 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16267021 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16267021 | pubmed:pagination | 9962-70 | lld:pubmed |
| pubmed-article:16267021 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:meshHeading | pubmed-meshheading:16267021... | lld:pubmed |
| pubmed-article:16267021 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16267021 | pubmed:articleTitle | Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. | lld:pubmed |
| pubmed-article:16267021 | pubmed:affiliation | Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. | lld:pubmed |
| pubmed-article:16267021 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16267021 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16267021 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16267021 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16267021 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16267021 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16267021 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16267021 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16267021 | lld:pubmed |
